blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3525792

EP3525792 - POWDER FOR ORAL SUSPENSION CONTAINING LAMOTRIGINE [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  15.08.2024
Database last updated on 03.10.2024
FormerRequest for examination was made
Status updated on  19.07.2019
FormerThe international publication has been made
Status updated on  20.04.2018
Most recent event   Tooltip15.08.2024Application deemed to be withdrawnpublished on 18.09.2024  [2024/38]
Applicant(s)For all designated states
Aucta Pharmaceuticals
675 US Route 1
North Brunswick, NJ 08902 / US
[2019/34]
Inventor(s)01 / LU, Enxian
347 Bromley Place
East Brunswick NJ 08816 / US
02 / LI, Shoufeng
20 Honeyman Road
Basking Ridge NJ 07920 / US
 [2019/34]
Representative(s)Cabinet Becker et Associés
25, rue Louis le Grand
75002 Paris / FR
[2019/34]
Application number, filing date17860743.811.10.2017
[2019/34]
WO2017US56146
Priority number, dateUS201662406624P11.10.2016         Original published format: US 201662406624 P
[2019/34]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018071547
Date:19.04.2018
Language:EN
[2018/16]
Type: A1 Application with search report 
No.:EP3525792
Date:21.08.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 19.04.2018 takes the place of the publication of the European patent application.
[2019/34]
Search report(s)International search report - published on:US19.04.2018
(Supplementary) European search report - dispatched on:EP24.03.2020
ClassificationIPC:A61K31/53, C07D253/075, A61K9/14, A61K9/10
[2020/17]
CPC:
A61K31/53 (EP,US); A61K9/1623 (US); A61K47/02 (EP,US);
A61K47/10 (EP,US); A61K47/36 (EP,US); A61K9/0095 (EP,US);
A61K9/10 (EP); A61K9/146 (EP); A61K9/1611 (US);
A61K9/1641 (US); A61K9/1652 (US); A61P25/00 (EP,US);
A61P25/24 (EP,US) (-)
Former IPC [2019/34]A61K31/53, C07D253/075, A61K9/14
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/34]
TitleGerman:PULVER FÜR ORALE SUSPENSIONEN MIT LAMOTRIGIN[2019/34]
English:POWDER FOR ORAL SUSPENSION CONTAINING LAMOTRIGINE[2019/34]
French:POUDRE POUR SUSPENSION ORALE CONTENANT DE LA LAMOTRIGINE[2019/34]
Entry into regional phase24.04.2019National basic fee paid 
24.04.2019Search fee paid 
24.04.2019Designation fee(s) paid 
24.04.2019Examination fee paid 
Examination procedure11.04.2019Observations by third parties
24.04.2019Examination requested  [2019/34]
26.10.2020Amendment by applicant (claims and/or description)
01.05.2024Application deemed to be withdrawn, date of legal effect  [2024/38]
24.05.2024Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2024/38]
Fees paidRenewal fee
28.10.2019Renewal fee patent year 03
27.10.2020Renewal fee patent year 04
27.10.2021Renewal fee patent year 05
27.03.2023Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
31.10.202206   M06   Fee paid on   27.03.2023
31.10.202307   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[IY]GB2278057  (WELLCOME FOUND [GB]) [I] 1-5,7-15 * pages 18,23 * * claim 14 * * the whole document *[Y] 1-5,7-15;
 [XYI]WO2007054975  (PANACEA BIOTEC LTD [IN], et al) [X] 1-15 * the whole document * * example 15 * [Y] 1-5,7-15 [I] 1-5,7-15;
 [IAY]US2010016322  (NAGARAJU NAGESH [IN], et al) [I] 1-5,7-15 * the whole document * * examples 3,7,8; tables 11-13 * [A] 6 [Y] 1-5,7-15;
    [XAYI] - A PRAMEELA RANI ET AL, "FULL FACTORIAL DESIGN IN FORMULATION OF LAMOTRIGINE SUSPENSION USING LOCUST BEAN GUM", INTERNATIONAL JOURNAL OF CHEMICAL SCIENCES, IN, (20130101), vol. 11, no. 2, ISSN 0972-768X, pages 751 - 760, XP055498437 [X] 13-15 * the whole document * * tables 2-3 * [A] 6 [Y] 1-5,7-15 [I] 1-5,7-15
    [XAYI] - Loyd V. Allen Jr., "Lamotrigine 1 mg/mL Oral Suspension", (20150515), pages 1 - 3, URL: https://www.uspharmacist.com/article/lamotrigine-1-mgml-oral-suspension, (20200312), XP055676193 [X] 1-5,7-10 * page 1, paragraph 1 * * page 2, lines 3-16 * [A] 6 [Y] 1-5,7-15 [I] 1-5,7-15
 [Y]  - Herbert A. Lieberman ET AL, "Pharmaceuticals Dosages Forms: Disperse Systems", PHARMACEUTICAL DOSAGE FORMS. DISPERSE SYSTEMS, NEW YORK* BASEL*HONG KONG, MARCEL DEKKER, (20050101), pages 162 - 163, ISBN 978-0-8247-9713-3, XP055676507 [Y] 1-5,7-15 * table 3 *
 [Y]  - SHARON ZIETSMAN ET AL, "Formulation Development and Stability Studies of Aqueous Metronidazole Benzoate Suspensions Containing Various Suspending Agents", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, US, (20070101), vol. 33, no. 2, doi:10.1080/03639040601011215, ISSN 0363-9045, pages 191 - 197, XP055625334 [Y] 1-5,7-15 * abstract * * page 197, column 1, lines 12-17 *

DOI:   http://dx.doi.org/10.1080/03639040601011215
International search[Y]US5556639  (FIELDEN KRYSTYNA E [GB]) [Y] 1 * entire document *;
 [A]US5861179  (HISKETT SIMON PHILIP [GB], et al) [A] 1-3, 18-20 * entire document *;
 [A]WO2005051350  (TORRENT PHARMACEUTICALS LTD [IN], et al) [A] 1-3, 18-20* entire document *;
 [A]US2005238724  (ARONHIME JUDITH [IL], et al) [A] 1-3, 18-20 * entire document *;
 [XY]  - RANI et al., "Full Factorial Design in Formulation of Lamotrigine Suspension Using Locust Bean Gum", International Journal of Chemical Sciences, vol. 11, no. 2, (20130000), pages 751 - 760, URL: http://www.tsijoumals.com/articles/full-factorial-design-in-formulation-of-lamotrigine-suspension-using-Iocust-bean-gum.pdf, (20171107), XP055498437 [X] 18, 20 [Y] 1
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.